Document Detail


Identifying factors that impact survival among women with inflammatory breast cancer.
MedLine Citation:
PMID:  21765048     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The objective of this retrospective study was to determine factors impacting survival among women with inflammatory breast cancer (IBC). METHODS: The Surveillance, Epidemiology and End Results Registry (SEER) was searched to identify women with stage III/IV IBC diagnosed between 2004 and 2007. IBC was identified within SEER as T4d disease as defined by the sixth edition of the American Joint Committee on Cancer. The Kaplan-Meier product-limit method was used to describe inflammatory breast cancer-specific survival (IBCS). Cox models were fitted to assess the multivariable relationship of various patient and tumor characteristics and IBCS. RESULTS: Two thousand three hundred and eighty-four women with stage IIIB/C and IV IBC were identified. Two-year IBCS among women with stage IIIB, IIIC and IV disease was 81%, 67% and 42%, respectively (P < 0.0001). In the multivariable model, patients with stage IIIB disease and those with stage IIIC disease had a 63% [hazard ratio (HR) 0.373, 95% confidence interval (CI) 0.296-0.470, P < 0.001] and 31% (HR 0.691, 95% CI 0.512-0.933, P = 0.016) decreased risk of death from IBC, respectively, compared with women with stage IV disease. Other factors significantly associated with decreased risk of death from IBC included low-grade tumors, being of white/other race, undergoing surgery, receiving radiation therapy and hormone receptor-positive disease. Among women with stage IV disease, those who underwent surgery of their primary had a 51% decreased risk of death compared with those who did not undergo surgery (HR = 0.489, 95% CI 0.339-0.704, P < 0.0001). CONCLUSIONS: Although IBC is an aggressive subtype of locally advanced breast cancer, it is heterogeneous with various factors affecting survival. Furthermore, our results indicate that a subgroup of women with stage IV IBC may benefit from aggressive combined modality management.
Authors:
S Dawood; N T Ueno; V Valero; W A Woodward; T A Buchholz; G N Hortobagyi; A M Gonzalez-Angulo; M Cristofanilli
Related Documents :
15298958 - Validation of p16ink4a as a marker of oncogenic human papillomavirus infection in cervi...
11588128 - A randomized, double blind, phase iii trial using oral beta-carotene supplementation fo...
18461608 - Hpv prevalence among healthy italian male sexual partners of women with cervical hpv in...
864848 - Prevalence and effects of parelaphostrongylus tenuis in a captive wapiti population.
23398678 - Patients with non-alcoholic fatty liver disease have higher risk of colorectal adenoma ...
8840418 - Youth suicide trends in california: an examination of immigrant and ethnic group risk.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-15
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  -     ISSN:  1569-8041     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-...
Next Document:  Is N-terminal probrain-type natriuretic peptide a clinically useful biomarker of volume overload in ...